These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
700 related articles for article (PubMed ID: 24009722)
1. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722 [TBL] [Abstract][Full Text] [Related]
2. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699 [TBL] [Abstract][Full Text] [Related]
3. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865 [TBL] [Abstract][Full Text] [Related]
4. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426 [TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival. Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673 [TBL] [Abstract][Full Text] [Related]
6. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. Healy JR; Hart LS; Shazad AL; Gagliardi ME; Tsang M; Elias J; Ruden J; Farrel A; Rokita JL; Li Y; Wyce A; Barbash O; Batra V; Samanta M; Maris JM; Schnepp RW Pediatr Blood Cancer; 2020 Jun; 67(6):e28267. PubMed ID: 32307821 [TBL] [Abstract][Full Text] [Related]
7. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
8. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205 [TBL] [Abstract][Full Text] [Related]
9. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377 [TBL] [Abstract][Full Text] [Related]
10. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782 [TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931 [TBL] [Abstract][Full Text] [Related]
13. Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. Lee S; Rellinger EJ; Kim KW; Craig BT; Romain CV; Qiao J; Chung DH Surgery; 2015 Sep; 158(3):819-26. PubMed ID: 26067464 [TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950 [TBL] [Abstract][Full Text] [Related]
15. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Misawa A; Hosoi H; Tsuchiya K; Sugimoto T Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580 [TBL] [Abstract][Full Text] [Related]
16. Targeting MYCN: a good BET for improving neuroblastoma therapy? Schnepp RW; Maris JM Cancer Discov; 2013 Mar; 3(3):255-7. PubMed ID: 23475876 [TBL] [Abstract][Full Text] [Related]
17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
18. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398 [TBL] [Abstract][Full Text] [Related]
19. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells. Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524 [TBL] [Abstract][Full Text] [Related]
20. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]